The study suggested a potentially crucial role of IGF-1R in ALK-mutated NB, proposing that co-targeting ALK and IGF-1R may be advantageous in the clinical treatment of ALK-mutated NB patients [165]. The gene discussed is IGF1R; the disease is neuroblastoma.